<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39569188</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics and antibody response to Omicron variants among solid carcinoma patients in China on the 2022.12-2023.4 wave of the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>1476186</StartPage><MedlinePgn>1476186</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1476186</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1476186</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">China experienced a surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants after adjusting its zero-coronavirus disease 2019 (COVID-19) policy. Although infections with Omicron variants are generally less severe than infections with previous SARS-CoV-2 variants, the clinical characteristics, persistent symptoms, and antibody responses in solid carcinoma patients (SCPs) with COVID-19 during the Omicron wave are unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a cross-sectional study in April 2023, recruiting healthy controls (HCs) from the community and SCPs from Zhejiang Provincial People's Hospital. Serum samples were collected, and a questionnaire was used to assess SARS-CoV-2 infection status, including demographic characteristics, clinical manifestations, and "long COVID" symptoms. Humoral immune responses were analyzed by enzyme-linked immunosorbent assays (ELISAs) targeting immunoglobulin G (IgG) antibodies against the receptor-binding domain (RBD; Omicron BA.4/5) protein and cell culture-based neutralization assays against Omicron variants (BA.4/5, BF.7, XBB.1.5, and EG.5).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In total, 298 SCPs and 258 HCs were enrolled. Self-reported COVID-19 case rates were significantly lower in SCPs than in HCs (78.5% vs. 93.8%, P&lt;0.001). Common COVID-19 symptoms were similar between the two groups, primarily comprising general (92.6% vs. 84.9%) and respiratory symptoms (51.9% vs. 48.2%) after acute infection. There was no significant difference in persistent symptoms at 1-3 months post-infection (P=0.353); fatigue was the most common symptom (45.0% vs. 44.8%). SCPs exhibited lower anti-RBD-IgG titers compared with HCs (1.061 vs. 1.978, P=0.001). The 50% pseudovirus neutralization titer (pVNT<sub>50</sub>) values for prevalent Omicron strains (BA.4/5 and BF.7) were lower in SCPs than in HCs (621.0 [288.8, 1333.0] vs. 894.1 [458.5, 1637.0] and 529.6 [215.3, 1264.5] vs. 463.1 [185.2, 914.0], respectively). Levels of antibodies against subsequent variants (XBB.1.5 and EG.5) also were reduced. There were no significant differences among carcinoma types in the levels of antibodies against Omicron variants. However, SCPs who received the SARS-CoV-2 vaccine or had COVID-19 during the Omicron wave displayed higher antibody levels.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This study elucidated the clinical and immunological characteristics of SCPs during the Omicron wave in China after the shift away from a zero-COVID-19 policy. Our findings provide insights regarding factors that influence COVID-19 symptoms and antibody levels in this population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Dai, Peng, Xu, Qin, Ding, Hua, Jiang, He and Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dai</LastName><ForeName>Rongrong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Public Health, Hangzhou Medical College, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Peng</LastName><ForeName>Weiyu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pathogen Microorganism Testing Institute, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Nani</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Pan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Xihu District Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Linling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Department of Prevention and Control of Infectious Disease, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Qianhui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Key Lab of Vaccine, Department of Prevention and Control of Infectious Disease, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jianmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Hangzhou Medical College, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Lab of Vaccine, Department of Prevention and Control of Infectious Disease, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hangjie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Prevention and Control of Infectious Disease, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002277" MajorTopicYN="N">Carcinoma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">antibody response</Keyword><Keyword MajorTopicYN="N">clinical characteristics</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">solid carcinoma</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39569188</ArticleId><ArticleId IdType="pmc">PMC11576375</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1476186</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xie D, Choi HK, Dalbeth N, Wallace ZS, Sparks JA, Lu N, et al. . Gout and excess risk of severe SARS-coV-2 infection among vaccinated individuals: A general population study. Arthritis Rheumatol. (2023) 75:122&#x2013;32. doi:&#xa0;10.1002/art.42339</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42339</ArticleId><ArticleId IdType="pmc">PMC9537980</ArticleId><ArticleId IdType="pubmed">36082457</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhl L, K&#xfc;hne JF, Beushausen K, Keil J, Christoph S, Sauer J, et al. . Third SARS-coV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. Front Immunol. (2023) 14:1120010. doi:&#xa0;10.3389/fimmu.2023.1120010</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1120010</ArticleId><ArticleId IdType="pmc">PMC10073596</ArticleId><ArticleId IdType="pubmed">37033958</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Liao Y, Yu X, Rong L, Chen B, Chen G, et al. . Clinical characteristics and prognostic factors of COVID-19 infection among cancer patients during the december 2022 - february 2023 omicron variant outbreak. Front In Med. (2024) 11:1401439. doi:&#xa0;10.3389/fmed.2024.1401439</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1401439</ArticleId><ArticleId IdType="pmc">PMC11171418</ArticleId><ArticleId IdType="pubmed">38873204</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Gao Z, Wang S. China's COVID-19 reopening measures-warriors and weapons. Lancet. (2023) 401:643&#x2013;4. doi:&#xa0;10.1016/S0140-6736(23)00213-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00213-1</ArticleId><ArticleId IdType="pmc">PMC9949835</ArticleId><ArticleId IdType="pubmed">36841613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Wang R, Jin P, Yu X, Wang W, Zhang Y, et al. . Clinical Characteristics and Outcomes of Liver Transplant Recipients Infected by Omicron During the Opening up of the Dynamic Zero-Coronavirus Disease Policy in China: A prospective, Observational Study. Am J Transplant. (2024) 24:631&#x2013;40. doi:&#xa0;10.1016/j.ajt.2023.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajt.2023.09.022</ArticleId><ArticleId IdType="pubmed">37863433</ArticleId></ArticleIdList></Reference><Reference><Citation>
Who COVID-19 Dashboard . Available online at: https://Data.Who.Int/Dashboards/COVID-19/Cases?M49=156 (Accessed October 15th, 2024).</Citation></Reference><Reference><Citation>Chen Y, Lin Y, Lu H, Wu X, Pan Y, Xia A, et al. . Real-World Effectiveness of Molnupiravir, Azvudine and Paxlovid against Mortality and Viral Clearance among Hospitalized Patients with COVID-19 Infection During the Omicron Wave in China: A Retrospective Cohort Study. Diagn Microbiol Infect Dis. (2024) 109:116353. doi:&#xa0;10.1016/j.diagmicrobio.2024.116353</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2024.116353</ArticleId><ArticleId IdType="pubmed">38776665</ArticleId></ArticleIdList></Reference><Reference><Citation>
Zero-COVID Policy Keeps Pandemic under Control . Available online at: https://english.www.gov.cn/news/topnews/202201/10/content_WS61db8e5cc6d09c94e48a3610.html (Accessed October 15th, 2024).</Citation></Reference><Reference><Citation>Wekking D, Senevirathne TH, Pearce JL, Aiello M, Scartozzi M, Lambertini M, et al. . The impact of COVID-19 on cancer patients. Cytokine Growth Factor Rev. (2024) 75:110&#x2013;8. doi:&#xa0;10.1016/j.cytogfr.2023.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2023.11.004</ArticleId><ArticleId IdType="pubmed">38103990</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q, Bates B, Shao YR, Hsu FC, Liu F, Madhira V, et al. . Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative. J Clin Oncol. (2022) 40:1414&#x2013;27. doi:&#xa0;10.1200/jco.21.02419</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.21.02419</ArticleId><ArticleId IdType="pmc">PMC9061155</ArticleId><ArticleId IdType="pubmed">35286152</ArticleId></ArticleIdList></Reference><Reference><Citation>Song NJ, Chakravarthy KB, Jeon H, Bolyard C, Reynolds K, Weller KP, et al. . Mrna vaccines against SARS-coV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer. J Immunother Cancer. (2024) 12(1):e007922. doi:&#xa0;10.1136/jitc-2023-007922</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2023-007922</ArticleId><ArticleId IdType="pmc">PMC10773442</ArticleId><ArticleId IdType="pubmed">38177076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bytyci J, Ying Y, Lee LYW. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review. Immun Inflammation Dis. (2024) 12:e1259. doi:&#xa0;10.1002/iid3.1259</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.1259</ArticleId><ArticleId IdType="pmc">PMC11044684</ArticleId><ArticleId IdType="pubmed">38661301</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. . Cancer patients in SARS-coV-2 infection: A nationwide analysis in China. Lancet Oncol. (2020) 21:335&#x2013;7. doi:&#xa0;10.1016/S1470-2045(20)30096-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaeddini M, Etemad-Moghadam S. SARS-COV-2 infection in cancer patients, susceptibility, outcome and care. Am J Med Sci. (2022) 364:511&#x2013;20. doi:&#xa0;10.1016/j.amjms.2022.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2022.05.017</ArticleId><ArticleId IdType="pmc">PMC9119956</ArticleId><ArticleId IdType="pubmed">35605680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin T, Li Y, Ying Y, Luo Z. Prevalence of comorbidity in chinese patients with COVID-19: systematic review and meta-analysis of risk factors. BMC Infect Dis. (2021) 21:200. doi:&#xa0;10.1186/s12879-021-05915-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-05915-0</ArticleId><ArticleId IdType="pmc">PMC7897883</ArticleId><ArticleId IdType="pubmed">33618678</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603&#x2013;5. doi:&#xa0;10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Seegers V, Rousseau G, Zhou K, Blanc-Lapierre A, Bigot F, Mahammedi H, et al. . COVID-19 infection despite previous vaccination in cancer patients and healthcare workers: results from a french prospective multicenter cohort (Papesco-19). Cancers (Basel). (2023) 15(19):4777. doi:&#xa0;10.3390/cancers15194777</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15194777</ArticleId><ArticleId IdType="pmc">PMC10571737</ArticleId><ArticleId IdType="pubmed">37835471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell ML, Catalfamo CJ, Farland LV, Ernst KC, Jacobs ET, Klimentidis YC, et al. . Post-acute sequelae of COVID-19 in a non-hospitalized cohort: results from the arizona covhort. PloS One. (2021) 16:e0254347. doi:&#xa0;10.1371/journal.pone.0254347</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254347</ArticleId><ArticleId IdType="pmc">PMC8336814</ArticleId><ArticleId IdType="pubmed">34347785</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. . Distinguishing features of long COVID identified through immune profiling. Nature. (2023) 623:139&#x2013;48. doi:&#xa0;10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehm J, Spaeth A, Dre&#xdf;ler L, Masetto T, Dannenberg R, Peter C, et al. . SARS-COV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients - a comparative long term post-infection study. Front Immunol. (2022) 13:915338. doi:&#xa0;10.3389/fimmu.2022.915338</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.915338</ArticleId><ArticleId IdType="pmc">PMC9428854</ArticleId><ArticleId IdType="pubmed">36059441</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen I, Campisi-Pfinto S, Rozenberg O, Colodner R, Bar-Sela G. The humoral response of patients with cancer to breakthrough COVID-19 infection or the fourth bnt162b2 vaccine dose. Oncologist. (2023) 28:e225&#x2013;e7. doi:&#xa0;10.1093/oncolo/oyad003</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oncolo/oyad003</ArticleId><ArticleId IdType="pmc">PMC10078898</ArticleId><ArticleId IdType="pubmed">36856804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zhang R, Qiao S, Wang X, Zhang W, Ruan W, et al. . Omicron SARS-COV-2 neutralization from inactivated and zf2001 vaccines. N Engl J Med. (2022) 387:277&#x2013;80. doi:&#xa0;10.1056/NEJMc2206900</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206900</ArticleId><ArticleId IdType="pmc">PMC9342420</ArticleId><ArticleId IdType="pubmed">35793198</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng W, Ma X, Tan K, Wang H, Cong M, Zhang Y, et al. . Evaluation of cross-neutralizing antibodies in children infected with omicron sub-variants. Lancet Reg Health West Pac. (2023) 40:100939. doi:&#xa0;10.1016/j.lanwpc.2023.100939</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100939</ArticleId><ArticleId IdType="pmc">PMC10632766</ArticleId><ArticleId IdType="pubmed">37953966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Xu N, Xu Y, Qin P, Dai R, Xu B, et al. . Safety and immunogenicity of ad5-ncov immunization after three-dose priming with inactivated SARS-COV-2 vaccine in chinese adults. Nat Commun. (2023) 14:4757. doi:&#xa0;10.1038/s41467-023-40489-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40489-2</ArticleId><ArticleId IdType="pmc">PMC10409730</ArticleId><ArticleId IdType="pubmed">37553338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C, Br&#xfc;ningk SC, Hoch T, Fan B, Muzio G, Thompson RC, et al. . Persistent complement dysregulation with signs of thromboinflammation in active long COVID. Science. (2024) 383:eadg7942. doi:&#xa0;10.1126/science.adg7942</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adg7942</ArticleId><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons RJ, Acharya P. Evolution of the SARS-COV-2 omicron spike. Cell Rep. (2023) 42:113444. doi:&#xa0;10.1016/j.celrep.2023.113444</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.113444</ArticleId><ArticleId IdType="pmc">PMC10782855</ArticleId><ArticleId IdType="pubmed">37979169</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiteri G, D'Agostini M, Abedini M, Ditano G, Collatuzzo G, Boffetta P, et al. . Protective Role of SARS-COV-2 Anti-S Igg against Breakthrough Infections among European Healthcare Workers During Pre and Post-Omicron Surge-Orchestra Project. Infection. (2024) 52(4):1347&#x2013;56. doi:&#xa0;10.1007/s15010-024-02189-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-024-02189-x</ArticleId><ArticleId IdType="pmc">PMC11289150</ArticleId><ArticleId IdType="pubmed">38326526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Guo L, Yuan J, Xu Z, Gu Y, Zhang J, et al. . Viral and antibody dynamics of acute infection with SARS-COV-2 omicron variant (B.1.1.529): A prospective cohort study from shenzhen, China. Lancet Microbe. (2023) 4:e632&#x2013;e41. doi:&#xa0;10.1016/s2666-5247(23)00139-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(23)00139-8</ArticleId><ArticleId IdType="pubmed">37459867</ArticleId></ArticleIdList></Reference><Reference><Citation>Regenhardt E, Kirsten H, Weiss M, L&#xfc;bbert C, Stehr SN, Remane Y, et al. . SARS-COV-2 vaccine breakthrough infections of omicron and delta variants in healthcare workers. Vaccines (Basel). (2023) 11(5):958. doi:&#xa0;10.3390/vaccines11050958</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11050958</ArticleId><ArticleId IdType="pmc">PMC10220865</ArticleId><ArticleId IdType="pubmed">37243062</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;raas A, Gr&#xf8;deland G, Granerud BK, Ueland T, Lind A, Fevang B, et al. . Breakthrough infections with the omicron and delta variants of SARS-COV-2 result in similar re-activation of vaccine-induced immunity. Front Immunol. (2022) 13:964525. doi:&#xa0;10.3389/fimmu.2022.964525</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.964525</ArticleId><ArticleId IdType="pmc">PMC9493489</ArticleId><ArticleId IdType="pubmed">36159859</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabani KIP, Weerasekara I, Damayanthi HDWT. COVID-19 vaccine acceptance and hesitancy among patients with cancer: A systematic review and meta-analysis. Public Health. (2022) 212:66&#x2013;75. doi:&#xa0;10.1016/j.puhe.2022.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2022.09.001</ArticleId><ArticleId IdType="pmc">PMC9452406</ArticleId><ArticleId IdType="pubmed">36244261</ArticleId></ArticleIdList></Reference><Reference><Citation>Poghosyan H, Ni Z, Vlahov D, Nelson L, Nam S. COVID-19 Vaccine Hesitancy among Medicare Beneficiaries with and without Cancer History: A Us Population-Based Study. J Community Health. (2023) 48:315&#x2013;24. doi:&#xa0;10.1007/s10900-022-01174-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10900-022-01174-5</ArticleId><ArticleId IdType="pmc">PMC9702715</ArticleId><ArticleId IdType="pubmed">36427111</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Li Y, Wang L, Zhao X, Ma X, Gao GF. Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey. Emerg Microbes Infect. (2023) 12:2258232. doi:&#xa0;10.1080/22221751.2023.2258232</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2258232</ArticleId><ArticleId IdType="pmc">PMC10512888</ArticleId><ArticleId IdType="pubmed">37691586</ArticleId></ArticleIdList></Reference><Reference><Citation>Passaro A, Peters S, Mok TSK, Attili I, Mitsudomi T, de Marinis F. Testing for COVID-19 in lung cancer patients. Ann Oncol. (2020) 31:832&#x2013;4. doi:&#xa0;10.1016/j.annonc.2020.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7144604</ArticleId><ArticleId IdType="pubmed">32278879</ArticleId></ArticleIdList></Reference><Reference><Citation>Donze C, Min V, Ninove L, de Lamballerie X, Revon Rivi&#xe8;re G, Verschuur A, et al. . Bnt162b2 COVID-19 vaccines in children, adolescents and young adults with cancer-a 1-year follow-up. Vaccines. (2023) 11(5):989. doi:&#xa0;10.3390/vaccines11050989</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11050989</ArticleId><ArticleId IdType="pmc">PMC10224057</ArticleId><ArticleId IdType="pubmed">37243093</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Wang G, Wang Y, Zhang Q, Ren L, Gu X, et al. . SARS-COV-2 -specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: A longitudinal cohort study. Lancet Microbe. (2022) 3:e348&#x2013;e56. doi:&#xa0;10.1016/S2666-5247(22)00036-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00036-2</ArticleId><ArticleId IdType="pmc">PMC8942480</ArticleId><ArticleId IdType="pubmed">35345417</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Zhang Q, Gu X, Ren L, Huang T, Li Y, et al. . Durability and cross-reactive immune memory to SARS-COV-2 in individuals 2 years after recovery from COVID-19: A longitudinal cohort study. Lancet Microbe. (2024) 5:e24&#x2013;33. doi:&#xa0;10.1016/S2666-5247(23)00255-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00255-0</ArticleId><ArticleId IdType="pmc">PMC10789611</ArticleId><ArticleId IdType="pubmed">38048805</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Qiao S, Dong L, Zhang R, Li R, Qin S, et al. . Antibody response assessment of immediate breakthrough infections after zero-COVID policy adjustment in China. Lancet Reg Health West Pac. (2023) 40:100945. doi:&#xa0;10.1016/j.lanwpc.2023.100945</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100945</ArticleId><ArticleId IdType="pmc">PMC10684796</ArticleId><ArticleId IdType="pubmed">38033432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun H, Nham E, Seong H, Yoon JG, Noh JY, Cheong HJ, et al. . Long-Term Humoral and Cellular Immunity against Vaccine Strains and Omicron Subvariants (Bq.1.1, Bn.1, Xbb.1, and Eg.5) after Bivalent COVID-19 Vaccination. Front Immunol. (2024) 15:1385135. doi:&#xa0;10.3389/fimmu.2024.1385135</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1385135</ArticleId><ArticleId IdType="pmc">PMC11096540</ArticleId><ArticleId IdType="pubmed">38756783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sil D, Gautam S, Saxena S, Joshi S, Kumar D, Mehta A, et al. . Comprehensive&#xa0;analysis of omicron subvariants: eg.5 rise, vaccination strategies, and global impact. Curr Drug Targets. (2024) 25:517&#x2013;25. doi:&#xa0;10.2174/0113894501296586240430061915</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0113894501296586240430061915</ArticleId><ArticleId IdType="pubmed">38726782</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a delphi consensus. Lancet Infect Dis. (2022) 22:e102&#x2013;e7. doi:&#xa0;10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. . Fatigue and&#xa0;cognitive&#xa0;impairment in post-COVID-19 syndrome: A systematic review and&#xa0;meta-analysis. Brain Behav Immun. (2022) 101:93&#x2013;135. doi:&#xa0;10.1016/j.bbi.2021.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>